First-line test for diagnosing acute babesiosis. Detects nucleic acid from B. microti and detects but does not differentiate between B. duncani, B. divergens, strain MO-1, and strain EU-1. Blood smears are also appropriate for diagnosing and monitoring babesiosis disease; refer to Parasites Smear (Giemsa Stain), Blood (0049025). If also investigating Anaplasmosis or Ehrlichiosis, consider Tick-Borne Disease Panel by PCR, Blood (2008670).
Qualitative Polymerase Chain Reaction
Lavender (EDTA) or Pink (K2EDTA).
Transport 1 mL whole blood. (Min: 0.6 mL)
Serum, plasma, and heparinized specimens.
Ambient: 24 hours; Refrigerated: 1 week; Frozen: 1 month
A negative result does not rule out the presence of PCR inhibitors in the patient specimen or test-specific nucleic acid in concentrations below the level of detection by this test.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
This test detects and speciates B. microti. The nucleic acid from B. duncani, B. divergens, strain MO-1, and strain EU-1 will be detected by this test but cannot be differentiated.
|Component Test Code*||Component Chart Name||LOINC|
|2008666||Babesia species by PCR||88233-2|
|2008668||Babesia microti by PCR||21089-8|